SER-109
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridioides Difficile Infection
Conditions
Clostridioides Difficile Infection
Trial Timeline
— → —
NCT ID
NCT02437500About SER-109
SER-109 is a pre-clinical stage product being developed by Seres Therapeutics for Clostridioides Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02437500. Target conditions include Clostridioides Difficile Infection.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02437500 | Pre-clinical | Completed |
| NCT03183141 | Phase 3 | Completed |
Competing Products
7 competing products in Clostridioides Difficile Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD5148 | AstraZeneca | Phase 2 | 52 |
| AZD5148 + Placebo | AstraZeneca | Phase 1 | 33 |
| C.difficile vaccine | Pfizer | Phase 3 | 76 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 74 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 74 |
| REC-3964 | Recursion Pharmaceuticals | Phase 2 | 47 |
| SER-109 | Seres Therapeutics | Phase 3 | 69 |